Lynn Elsenhans - GlaxoSmithKline Plc Independent Non-Executive Director
GSKN Stock | MXN 655.00 0.00 0.00% |
Director
Ms. Lynn Laverty Elsenhans is NonExecutive Independent Director of GlaxoSmithKline Plc., since 1 July 2012. Lynn has a wealth of experience of running a global business and significant knowledge of the global markets in which GSK operates. She served as Chair, President and Chief Executive Officer of Sunoco Inc from 2009 to 2012. Prior to joining Sunoco in 2008 as President and Chief Executive Officer, Lynn worked for Royal Dutch Shell, which she joined in 1980, and where she held a number of senior roles, including Executive Vice President, Global Manufacturing from 2005 to 2008. Lynn was previously a NonExecutive Director of Flowserve Corporation and The First Tee of Greater Houston. Lynn is a NonExecutive Director of Baker Hughes, a GE company, and Chair of its Audit Committee, and a Director of the Texas Medical Center. She is also a Trustee of the United Way of Greater Houston. since 2012.
Age | 61 |
Tenure | 12 years |
Phone | 44 20 8047 5000 |
Web | https://www.gsk.com |
GlaxoSmithKline Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GlaxoSmithKline Plc's management efficiency ratios could be used to measure how well GlaxoSmithKline Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Roberto Heredia | Grupo Sports World | N/A | |
Enrique HernandezPulido | Grupo Sports World | N/A | |
Luis Barcena | Grupo Sports World | 43 | |
Luis MacKissack | Grupo Sports World | 55 | |
Shellye Archambeau | Verizon Communications | 55 | |
Gregory Weaver | Verizon Communications | 65 | |
Cynthia Ayon | Grupo Sports World | 52 | |
David Teatum | Grupo Sports World | N/A | |
Melanie Healey | Verizon Communications | 56 | |
Richard Carrion | Verizon Communications | 65 | |
Andrea Zullo | Grupo Sports World | N/A | |
Patricia Menendez | Grupo Sports World | N/A | |
Martha Keeth | Verizon Communications | 71 | |
Humberto Herrera | Grupo Sports World | 46 | |
Cosme Martinez | Grupo Sports World | 56 | |
Enrique Mejorada | Southern Copper | 62 | |
Luis Platas | Grupo Sports World | N/A | |
Laura Peterson | Air Transport Services | 58 | |
Richard Rexach | Verizon Communications | 63 | |
Carlos Elizondo | Grupo Sports World | 44 | |
Clarence Otis | Verizon Communications | 61 |
Management Performance
Return On Equity | 0.31 | |||
Return On Asset | 0.0659 |
GlaxoSmithKline plc Leadership Team
Elected by the shareholders, the GlaxoSmithKline Plc's board of directors comprises two types of representatives: GlaxoSmithKline Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Plc's management team and ensure that shareholders' interests are well served. GlaxoSmithKline Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director | ||
Lynn Elsenhans, Independent Non-Executive Director | ||
Luke Miels, President - Global Pharmaceuticals | ||
Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
Daniel Podolsky, Non-Executive Independent Director | ||
Emma Walmsley, President - Consumer Healthcare Worldwide | ||
Luc Debruyne, President - Global Vaccines | ||
Andrew Witty, CEO, Executive Director | ||
Brian McNamara, CEO - GSK Consumer Healthcare | ||
Roy Anderson, Non-Executive Independent Director | ||
Philip Hampton, Independent Non-Executive Director | ||
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
Vivienne Cox, Non-Executive Director | ||
Bill Louv, Senior Vice President - Core Business Services | ||
Diana Conrad, Chief Officer | ||
Roger Connor, President - Global Manufacturing & Supply | ||
Abbas Hussain, President Global Pharmaceuticals | ||
Phil Thomson, Senior Vice President - Global Communications | ||
Judy Lewent, Non-Executive Independent Director | ||
Hans Wijers, Independent Non-Executive Director | ||
Shobie Ramakrishnan, Chief Officer | ||
Sarah EltonFarr, Head Relations | ||
Stephanie Burns, Non-Executive Independent Director | ||
Julie Brown, Chief Officer | ||
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
Urs Rohner, Non-Executive Independent Director | ||
Marvinder Banga, Senior Non-Executive Independent Director | ||
Deryck Maughan, Senior Independent Non-Executive Director | ||
Jesse Goodman, Non-Executive Director | ||
Laurie Glimcher, Non-Executive Director | ||
Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
Sally Jackson, VP Office | ||
James Ford, Sr Compliance | ||
Victoria Whyte, Company Secretary | ||
Daniel Troy, Sr. VP and General Counsel | ||
Shah Hussain, President - Europe, Japan & EMAP | ||
Tony Wood, Chief Officer | ||
Manvinder Banga, Non-Executive Director | ||
David Redfern, Chief Strategy Officer | ||
Patrick Vallance, President - Pharmaceuticals R&D | ||
Stacey Cartwright, Non-Executive Independent Director | ||
Regis Simard, President - Pharmaceutical Supply Chain | ||
Iain Mackay, CFO - Designate, Executive Director | ||
Karenann Terrell, Chief Digital & Technology Officer | ||
Claire Thomas, Senior Vice President - Human Resources |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.31 | |||
Return On Asset | 0.0659 | |||
Profit Margin | 0.51 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 1.79 T | |||
Shares Outstanding | 2.05 B | |||
Shares Owned By Insiders | 0.02 % | |||
Shares Owned By Institutions | 14.10 % | |||
Price To Earning | 11.33 X | |||
Price To Book | 6.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Transaction History View history of all your transactions and understand their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |